The Bio Report

563 Episodes

1. Harnessing Biology to Address Global Challenges

   Published: 10/29/2015
2. Immunotherapies ETF Lets Biotech Investors Bet on Emerging Sector

   Published: 10/22/2015
3. Biotech Investors Turn Their Eyes to Policy Matters

   Published: 10/16/2015
4. Why the MedTech Industry Should Worry About Future Innovation

   Published: 10/8/2015
5. Rare Disease Drug Developer Shows Speed of Business Model

   Published: 10/1/2015
6. Ensuring Value-Based Care Addresses What Matters to Patients

   Published: 9/24/2015
7. California, Aid-in-Dying, and What We’ve Learned from Oregon

   Published: 9/17/2015
8. FDA Guidance on Names for Biologics and Biosimilars and its Implications

   Published: 9/10/2015
9. Understanding the Cost and Value of Cancer Therapies

   Published: 9/3/2015
10. Jimmy Carter’s Final Wish: Eradicating Guinea Worm

    Published: 8/27/2015
11. The Quest for a Pink Viagra

    Published: 8/20/2015
12. Free Speech Ruling May Force FDA to Rethink Off-Label Marketing

    Published: 8/14/2015
13. Drugmakers Often Late to Report Serious Side Effects

    Published: 8/6/2015
14. When Hospital Cause, Rather than Cure, Deadly Infections

    Published: 7/30/2015
15. Rethinking the Value and Price of Drugs

    Published: 7/23/2015
16. Harnessing Stem Cells to Test Drug Safety

    Published: 7/16/2015
17. CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries

    Published: 7/9/2015
18. Biotech’s Record Performance and Looming Threats

    Published: 7/2/2015
19. What a Decade of Investment Tells Us about the Health of Biotech

    Published: 6/25/2015
20. What Activist Investors Can Teach Biotech Companies

    Published: 6/18/2015